Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.70 |
| ▸ | FAP | Q12884 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Anhydrous SCHEMBL18894359 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL29355255 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL2040329 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL39724 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL18492311 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL20295138 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL19586794 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL3133933 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL400718 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL22206868 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497435-B2 | Multimerization of IL-15/IL-15R-alpha-fc complexes to enhance immunotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-16 | — | — | US | claimed |
| CN-115524408-B | Detection method of related substances in emtricitabine propofol tenofovir disoproxil fumarate compound preparation | 成都倍特药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-115524408-A | Method for detecting related substances in emtricitabine-propofol-tenofovir tablet compound preparation | 成都倍特药业股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| US-20220241301-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND | EVOFEM INC (US) | 2022-08-04 | — | — | US | claimed |
| US-20220106375-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-07 | — | — | US | claimed |
| US-20210179647-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | claimed |
| EP-3808752-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-04-21 | — | — | EP | claimed |
| CN-108948084-B | Tenofovir di-L-amino acid ester and preparation method thereof | 浙江司太立制药股份有限公司 | 2020-10-20 | — | — | CN | claimed |
| US-20200069708-A1 | TOPICAL ANTIVIRAL FORMULATIONS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | claimed |
| EP-3333173-B1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2019-06-26 | — | — | EP | claimed |
| EP-1163256-B1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS EDEN PHARMACEUTICALS (US) | 2004-02-18 | — | — | EP | claimed |
| EP-0915894-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2003-05-14 | — | — | EP | claimed |
| EP-1243593-A2 | Nucleotide analog composition and synthesis method | GILEAD SCIENCES, INC. (US) | 2002-09-25 | — | — | EP | claimed |
| US-6093816-A | Cationic lipids | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-25 | — | — | US | claimed |
| US-6057305-A | Antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2000-05-02 | — | — | US | claimed |
| EP-0654037-B1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1999-05-12 | — | — | EP | claimed |
| US-5763424-A | SEQUESTERING AGENT | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | claimed |
| WO-1996040704-A1 | PYRAZOLE-RELATED DERIVATIVES ENDOWED WITH ANTITUMOR AND ANTIVIRAL ACTIVITIES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM SARC S.C.R.L. (IT) | 1996-12-19 | — | — | WO | claimed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | claimed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241301-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND | ALG8, ALG1, EIF2AK2 | CYP3A4 3892/4885CYP2D6 3760/4885FAP 4296/4885 |
| US-20210179647-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC10A1, PYGL, HASPIN | CYP3A4 960/4885CYP2D6 2025/4885FAP 997/4885 |
| US-20200069708-A1 | TOPICAL ANTIVIRAL FORMULATIONS | TYMP, PNP, SLC29A1 | CYP3A4 2902/4885CYP2D6 984/4885FAP 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.